文献速递生殖医学

口服微粒化黄体酮行卵巢刺激与GnRH拮抗剂方案后的卵巢反应及胚胎倍性:一项重复卵巢刺激周期的前瞻性研究

Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles.
PubMed 文献 · Hum Reprod · 2024-01-01

44名女性在6个月内先后接受GnRH拮抗剂方案和口服微粒化黄体酮PPOS方案,固定rFSH剂量,所有囊胚行PGT-A。PPOS组获卵数、MII卵数和2PN数显著高于拮抗剂组,但囊胚数、活检囊胚数和整倍体胚胎数无显著差异。作者认为冻胚全胚策略下可安全考虑口服微粒化黄体酮控制LH峰。

要点

  • PPOS组获卵数、MII卵数和2PN数显著高于GnRH拮抗剂组。
  • 两组囊胚数、活检囊胚数和整倍体胚胎数无显著差异。
  • 作者认为冻胚全胚策略下可安全考虑口服微粒化黄体酮控制LH峰。

核心结论

  • 口服微粒化黄体酮行PPOS可获更多卵母细胞,整倍体囊胚数与GnRH拮抗剂方案相当。

研究设计与样本

  • 前瞻性研究,2019年9月至2022年1月纳入44名女性,每人在6个月内先后接受GnRH拮抗剂方案和口服微粒化黄体酮PPOS方案各一个周期,两周期rFSH固定剂量相同(225或300 IU)。
  • 首个周期为灵活GnRH拮抗剂方案(0.25 mg/日,当卵泡达14 mm时启动),洗脱1个月后第二周期为口服微粒化黄体酮200 mg从刺激第1天开始。
  • 所有生成的囊胚均行PGT-A。

主要发现

  • PPOS组与拮抗剂组获卵数分别为12.7±8.09与10.3±5.84(均值差-2.4,95%CI -4.1至-0.73),MII卵数分别为9.1±6.12与7.3±4.15(均值差-1.8,95%CI -3.1至-0.43),2PN数分别为7.1±4.99与5.7±3.35(均值差-1.5,95%CI -2.6.1至-0.32)。
  • PPOS组与拮抗剂组囊胚数分别为2.9±2.11与2.8±2.12(均值差-0.07,95%CI -0.67至0.53),活检囊胚数分别为2.9±2.16与2.9±2.15(均值差-0.07,95%CI -0.70至0.56),均无显著差异。
  • PPOS组与拮抗剂组每个活检胚胎的整倍体率分别为29%(95%CI 21.8-38.1%)与35%(95%CI 26.6-43.9%)。
  • 主要结局平均整倍体胚胎数PPOS组为0.86±0.90,拮抗剂组为1.00±1.12,无显著差异。
  • 触发日激素谱除FSH外各激素在两组间均有统计学显著差异,PPOS周期血清E2、LH和孕酮水平均更高。

临床怎么用

  • 作者认为在冻胚全胚策略下,临床医生可安全考虑口服微粒化黄体酮控制LH峰,患者可受益于口服给药的优势,获卵数可能更高且成本更低,而不影响胚胎倍性率。

局限性

  • 研究检验效能针对平均整倍体胚胎数差异,而非妊娠结局。
  • 按方案无随机化,第一周期始终为GnRH拮抗剂周期,第二周期为PPOS,中间间隔1个月洗脱期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there any difference in ovarian response and embryo ploidy following progesterone-primed ovarian stimulation (PPOS) using micronized progesterone or GnRH antagonist protocol? SUMMARY ANSWER: Pituitary downregulation with micronized progesterone as PPOS results in higher number of oocytes retrieved and a comparable number of euploid blastocysts to a GnRH antagonist protocol. WHAT IS KNOWN ALREADY: Although the GnRH antagonist is considered by most the gold standard protocol for controlling the LH surge during ovarian stimulation (OS) for IVF/ICSI, PPOS protocols are being increasingly used in freeze-all protocols. Still, despite the promising results of PPOS protocols, an early randomized trial reported potentially lower live births in recipients of oocytes resulting following downregulation with medroxyprogesterone acetate as compared with a GnRH antagonist protocol. The scope of the current prospective study was to investigate whether PPOS with micronized progesterone results in an equivalent yield of euploid blastocysts to a GnRH antagonist protocol. STUDY DESIGN, SIZE, DURATION: In this prospective study, performed between September 2019 to January 2022, 44 women underwent two consecutive OS protocols within a period of 6 months in a GnRH antagonist protocol or in a PPOS protocol with oral micronized progesterone. PARTICIPANTS/MATERIALS, SETTING, METHODS: Overall, 44 women underwent two OS cycles with an identical fixed dose of rFSH (225 or 300 IU) in both cycles. Downregulation in the first cycles was performed with the use of a flexible GnRH antagonist protocol (0.25 mg per day as soon as one follicle of 14 mm) and consecutively, after a washout period of 1 month, control of LH surge was performed with 200 mg of oral micronized progesterone from stimulation Day 1. After the completion of both cycles, all generated blastocysts underwent genetic analysis for aneuploidy screening (preimplantation genetic testing for aneuplody, PGT-A). MAIN RESULTS AND THE ROLE OF CHANCE: Comparisons between protocols did not reveal differences between the duration of OS. The hormonal profile on the day of trigger revealed statistically significant differences between protocols in all the tested hormones except for FSH: with significantly higher serum E2 levels, more elevated LH levels and higher progesterone levels in PPOS cycles as compared with antagonist cycles, respectively. Compared with the GnRH antagonist protocol, the PPOS protocol resulted in a significantly higher number of oocytes (12.7 ± 8.09 versus 10.3 ± 5.84; difference between means [DBM] -2.4 [95% CI -4.1 to -0.73]), metaphase II (9.1 ± 6.12 versus 7.3 ± 4.15; DBM -1.8 [95% CI -3.1 to -0.43]), and 2 pronuclei (7.1 ± 4.99 versus 5.7 ± 3.35; DBM -1.5 [95% CI -2.6.1 to -0.32]), respectively. Nevertheless, no differences were observed regarding the mean number of blastocysts between the PPOS and GnRH antagonist protocols (2.9 ± 2.11 versus 2.8 ± 2.12; DBM -0.07 [95% CI -0.67 to 0.53]) and the mean number of biopsied blastocysts (2.9 ± 2.16 versus 2.9 ± 2.15; DBM -0.07 [95% CI -0.70 to 0.56]), respectively. Concerning the euploidy rates per biopsied embryo, a 29% [95% CI 21.8-38.1%] and a 35% [95% CI 26.6-43.9%] were noticed in the PPOS and antagonist groups, respectively. Finally, no difference was observed for the primary outcome, with a mean number of euploid embryos of 0.86 ± 0.90 versus 1.00 ± 1.12 for the comparison of PPOS versus GnRh antagonist. LIMITATIONS, REASONS FOR CAUTION: The study was powered to detect differences in the mean number of euploid embryos and not in terms of pregnancy outcomes. Additionally, per protocol, there was no randomization, the first cycle was always a GnRH antagonist cycle and the second a PPOS with 1 month of washout period in between. WIDER IMPLICATIONS OF THE FINDINGS: In case of a freeze-all protocol, clinicians may safely consider oral micronized progesterone to control the LH surge and patients could benefit from the advantages of a medication of oral administration, with a potentially higher number of oocytes retrieved at a lower cost, without any compromise in embryo ploidy rates. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by an unrestricted grant from Theramex. N.P.P. has received Research grants from Merck Serono, Organon, Ferring Pharmaceutical, Roche, Theramex, IBSA, Gedeon Richter, and Besins Healthcare; honoraria for lectures from: Merck Serono, Organon, Ferring Pharmaceuticals, Besins International, Roche Diagnostics, IBSA, Theramex, and Gedeon Richter; consulting fees from Merck Serono, Organon, Besins Healthcare, and IBSA. M.d.M.V., F.M., and I.R. declared no conflicts of interest. TRIAL REGISTRATION NUMBER: The study was registered at Clinical Trials Gov. (NCT04108039).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Vidal MDM, Martínez F, Rodríguez I, et al. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles. Hum Reprod. 2024. PMID: 38498835. doi:10.1093/humrep/deae047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。